A top wall street analyst believes CRISPR Therapeutics' stock could more than double, prompting consideration of whether to buy the stock. The company's stock has experienced significant fluctuations, with a 58% surge over the past year and a recent roller-coaster ride. Some outlets suggest the stock is a good investment, while others discuss the volatility, and separate reports mention other biotech companies, such as Kyverna and Viking Therapeutics, experiencing stock movements.